





Kırım-Kongo Kanamalı Ateşi

Konsorsiyum Verileri

25 Nisan 2025
Klimik Kongresi



Giriş



Fanelli A, Schnitzler JC, De Nardi M, Donachie A, Capua I, Lanave G, Buonavoglia D, Caceres-Soto P, Tizzani P. Euro Surveill. 2023


KIRIM-KONGO
KANAMALI ATEŞİ
ÇALIŞMA GRUBU

20 OCAK 2024

08.30 - 18:00

**Koç Üniversitesi Hastanesi,
KUISCID**

KUISCID KOÇ UNIVERSITY - İŞBANK
CENTER FOR INFECTIOUS DISEASES




Crimean-Congo Haemorrhagic Fever Geographic Distribution

50° North limit for *Hyalomma* ticks




>30 000 cases
2-40% fatality



Greece : 2008, Agai virus
India : 2011
Spain : 2016
Portekiz : 2024



ECDC: by 23 October 2024





KKKA Ağı

Yöntem

- Türkiye'de 18 hastanedeki veriler
- 1 Ocak 2019 ile 31 Aralık 2024 tarihleri arasında
- Laboratuvarla doğrulanmış 1103 KKKA hastası

Amaç

Ağır hastalık gelişimini öngören belirteçlerin tanımlanması ve erken tanınması yoluyla klinik karar alma süreçlerine rehberlik etmek ve hasta sonuçlarını iyileştirmek.




Fig 1. Vaka dağılım haritası





Fig 2. Yıllara göre vaka sayısı ve fatalite hızları.




Hasta Demografik Bilgileri

SEX DISTRIBUTION




AGE DISTRIBUTION






Hasta Demografik Bilgileri

OCCUPATION




TRANSMISSION ROUTE






Hasta Demografik Bilgileri

INCUBATION PERIOD



HOSPITALIZATION AFTER SYMPTOMS






Sonuçlar

ICU Admission						
Variable	n (%)	Not Admitted n (%)	Admitted n (%)	Odds Ratio	95% CI	p-value
Sex						
Female	377 (34.2)	346 (34.1)	31 (35.2)	0.952	0.603-1.503	0.834
Male	725 (65.8)	668 (65.9)	57 (64.8)			
Age						
<65 years	830 (76.5)	770 (77.2)	60 (68.2)	1.583	0.987-2.539	0.055
≥65 years	255 (23.5)	227 (22.8)	28 (31.8)			
Occupation						
Farmer	838 (76.0)	779 (76.7)	59 (67.0)	0.616	0.386-0.984	0.041
Others	265 (24.0)	236 (23.3)	29 (33.0)			
Hospitalization After Symptom Onset						
<4 days	658 (59.6)	616 (62.3)	42 (50.6)	1.616	1.032-2.533	0.035
≥4 days	413 (37.4)	372 (37.7)	41 (49.4)			
Clinical Symptoms						
Fever	849 (77.0)	779 (76.7)	70 (79.5)	1.178	0.688-2.018	0.550
Myalgia	793 (71.9)	746 (73.5)	47 (53.4)	0.413	0.266-0.643	<0.001
Abdominal Pain	268 (24.3)	244 (24.0)	24 (27.3)	1.185	0.725-1.936	0.498
Vomiting	453 (41.1)	417 (41.1)	36 (40.9)	0.993	0.638-1.546	0.975
Diarrhea	293 (26.6)	260 (25.6)	33 (37.5)	1.742	1.107-2.743	0.015
Headache	568 (51.5)	531 (52.3)	37 (42.0)	0.661	0.426-1.028	0.064
Conjunctivitis	174 (15.8)	168 (16.6)	6 (6.8)	0.369	0.158-0.859	0.016
Rash	161 (14.6)	150 (14.8)	11 (12.5)	0.824	0.428-1.586	0.561
Hemorrhage	172 (15.6)	145 (14.3)	27 (30.7)	2.656	1.634-4.318	<0.001
Fatigue	950 (86.1)	885 (87.2)	65 (73.9)	0.415	0.249-0.691	<0.001
Loss of appetite	376 (34.1)	350 (34.5)	26 (29.5)	0.797	0.495-1.282	0.349
Hemorrhage Type						
No Hemorrhage	943 (85.5)	882 (86.9)	61 (69.3)	1 (ref)		
Petechiae	41 (3.7)	38 (3.7)	3 (3.4)	1.142	0.343-3.804	0.829
Ecchymosis	19 (1.7)	17 (1.7)	2 (2.3)	1.701	0.384-7.532	0.484
Hemorrhage	100 (9.1)	78 (7.7)	22 (25.0)	4.078	2.377-6.996	<0.001

Hemorrhage Site						
Gingival	44 (4.0)	35 (3.4)	9 (10.2)	3.190	1.481-6.873	0.006
Epistaxis	53 (4.8)	43 (4.2)	10 (11.4)	2.898	1.403-5.988	0.007
Vaginal	32 (2.9)	29 (2.9)	3 (3.4)	1.200	0.358-4.021	0.737
Rectal	20 (1.8)	13 (1.3)	7 (8.0)	6.661	2.586-17.16	<0.001
Comorbidities						
Diabetes Mellitus	65 (5.9)	55 (5.4)	10 (11.4)	2.238	1.098-4.562	0.023
Chronic Heart Disease	51 (4.6)	44 (4.3)	7 (8.0)	1.907	0.832-4.370	0.178
Hypertension	88 (8.0)	78 (7.7)	10 (11.4)	1.540	0.767-3.094	0.222
Secondary Bacterial Infection						
Yes	51 (4.6)	29 (2.9)	22 (25.0)	11.33	6.173-20.81	<0.001
No	1052 (95.4)	986 (97.1)	66 (75.0)			
Treatment						
Ribavirin	401 (36.4)	371 (36.6)	30 (34.1)	0.898	0.567-1.421	0.645
Vitamin K	16 (1.5)	4 (0.4)	12 (13.8)	39.44	12.42-125.3	<0.001
Plasmapheresis	34 (3.2)	7 (0.7)	27 (31.0)	63.06	26.39-150.7	<0.001
Fresh Frozen Plasma	189 (17.4)	143 (14.3)	46 (52.3)	6.548	4.158-10.31	<0.001
Dexamethasone	189 (17.4)	143 (14.3)	46 (52.3)	6.548	4.158-10.31	<0.001
Prednisolone	61 (5.7)	40 (4.0)	21 (24.4)	7.673	4.275-13.77	<0.001
Thrombocyte	335 (30.8)	265 (26.5)	70 (79.5)	10.80	6.315-18.47	<0.001
Erythrocyte Suspension	48 (4.5)	25 (2.5)	23 (26.4)	13.77	7.406-25.61	<0.001
Ribavirin Treatment Initiation						
<24 hours	91 (8.25)	88 (23.7)	3 (10.0)	0.357	0.106-1.206	0.084
<48 hours	177 (16.0)	170 (45.8)	7 (23.3)	0.360	0.151-0.859	0.017
<72 hours	253 (22.9)	241 (65.0)	12 (40.0)	0.360	0.168-0.770	0.006
<96 hours	319 (28.9)	303 (81.7)	16 (53.3)	0.256	0.119-0.551	<0.001




Sonuçlar





Sonuçlar





Sonuçlar

Variable	ICU Admission			Mortality		
	OR	95% CI	p-value	OR	95% CI	p-value
Male Sex	0.890	0.377-2.098	0.790	1.351	0.724-2.520	0.344
Age ≥65 years	1.952	0.827-4.609	0.127	2.098	1.162-3.791	0.014
Farmer	0.445	0.186-1.062	0.068	0.576	0.315-1.054	0.073
DM	3.606	1.062-12.24	0.040	4.204	1.862-9.493	<0.001
CHD	1.979	0.389-10.07	0.411	1.392	0.491-3.947	0.535
HTN	1.276	0.333-4.898	0.722	0.787	0.300-2.069	0.627
Ribavirin Initiation <48 hours	0.399	0.160-0.993	0.048	1.109	0.504-2.440	0.797
Secondary Bacterial Infection	8.633	2.443-30.51	<0.001	2.942	1.219-7.101	0.016



ESCMID Global: Viyana, 11-15 Nisan 2025

